Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 29 10:10AM ET
Dollar change
Percentage change
Index- P/E191.46 EPS (ttm)0.60 Insider Own3.12% Shs Outstand63.21M Perf Week-2.44%
Market Cap7.26B Forward P/E5.81 EPS next Y19.85 Insider Trans-0.85% Shs Float60.99M Perf Month-7.66%
Income79.95M PEG17.09 EPS next Q5.13 Inst Own90.58% Short Float / Ratio4.21% / 3.87 Perf Quarter-20.59%
Sales3.79B P/S1.91 EPS this Y39.75% Inst Trans-0.76% Short Interest2.57M Perf Half Y-9.96%
Book/sh55.44 P/B2.08 EPS next Y7.62% ROA0.74% Target Price194.44 Perf Year-25.05%
Cash/sh25.19 P/C4.58 EPS next 5Y11.20% ROE2.56% 52W Range111.25 - 160.96 Perf YTD-27.57%
Dividend- P/FCF5.84 EPS past 5Y- ROI0.92% 52W High-28.31% Beta0.66
Dividend %- Quick Ratio1.67 Sales past 5Y17.93% Gross Margin71.28% 52W Low3.72% ATR3.76
Employees2800 Current Ratio2.06 Sales Q/Q3.35% Oper. Margin14.99% RSI (14)36.56 Volatility3.04% 3.26%
OptionableYes Debt/Eq1.66 EPS Q/Q758.17% Profit Margin2.11% Rel Volume0.69 Prev Close114.49
ShortableYes LT Debt/Eq1.48 EarningsNov 08 AMC Payout- Avg Volume663.62K Price115.39
Recom1.56 SMA20-6.76% SMA50-9.63% SMA200-13.75% Volume67,102 Change0.79%
Date Action Analyst Rating Change Price Target Change
Nov-27-23Downgrade UBS Buy → Neutral $170 → $135
Sep-29-23Initiated Raymond James Mkt Perform
Jun-12-23Resumed Wells Fargo Equal Weight $184 → $140
Dec-09-22Upgrade Goldman Neutral → Buy $192 → $190
Jun-14-22Initiated UBS Buy $194
Apr-06-22Downgrade Goldman Buy → Neutral $202 → $196
Nov-19-21Resumed Goldman Buy $198
Oct-07-21Resumed Jefferies Buy $172
Oct-05-21Initiated Citigroup Buy $200
Sep-23-21Initiated Needham Buy $220
Nov-27-23 09:49AM
Nov-15-23 05:21AM
Nov-14-23 12:50PM
Nov-09-23 05:07PM
07:00PM Loading…
Nov-08-23 07:00PM
Nov-07-23 12:33PM
Nov-01-23 04:15PM
Oct-31-23 05:42PM
Oct-30-23 04:05PM
11:40AM Loading…
Oct-26-23 11:40AM
Oct-25-23 04:15PM
Oct-23-23 07:45AM
Oct-21-23 06:38AM
Oct-20-23 10:30AM
Oct-18-23 07:55AM
Oct-17-23 09:55AM
Oct-16-23 07:45AM
Oct-13-23 08:15AM
Oct-10-23 11:40AM
Oct-06-23 10:15AM
02:58PM Loading…
Oct-04-23 02:58PM
Oct-02-23 05:21AM
Sep-30-23 05:06AM
Sep-27-23 02:38PM
Sep-22-23 11:57AM
Sep-21-23 05:41PM
Sep-20-23 02:15PM
Sep-19-23 06:45AM
Sep-13-23 04:15PM
Sep-12-23 07:30AM
Sep-11-23 07:45AM
Sep-08-23 11:30AM
Aug-26-23 07:25AM
Aug-24-23 04:15PM
Aug-15-23 09:01PM
Aug-11-23 07:45PM
Aug-09-23 09:00PM
Aug-08-23 11:37PM
Aug-02-23 02:10PM
Jul-28-23 10:56AM
Jul-27-23 10:25AM
Jul-26-23 04:15PM
Jul-21-23 08:08AM
Jul-19-23 09:55AM
Jul-11-23 11:40AM
Jul-08-23 05:06AM
Jul-07-23 12:00PM
Jun-23-23 09:57AM
Jun-21-23 08:00PM
Jun-09-23 11:30AM
Jun-02-23 06:41PM
May-31-23 07:45AM
May-30-23 04:15PM
May-25-23 04:15PM
May-10-23 07:00PM
May-08-23 10:00AM
May-05-23 03:44PM
May-02-23 04:15PM
Apr-27-23 07:30AM
Apr-26-23 08:00PM
Apr-19-23 07:45AM
Apr-14-23 11:30AM
Mar-31-23 11:30AM
Mar-30-23 07:44AM
Mar-21-23 06:45AM
Mar-15-23 07:00AM
Mar-08-23 08:00AM
Mar-06-23 01:07AM
Mar-03-23 01:31PM
Mar-01-23 05:35PM
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patil Neena MEVP & Chief Legal OfficerSep 01Sale144.251,500216,37529,186Sep 06 05:09 PM
Carr PatriciaSVP, Chief Accounting OfficerAug 29Sale143.4714220,3735,986Aug 31 06:44 PM
Patil Neena MEVP & Chief Legal OfficerAug 15Sale139.59750104,69530,686Aug 17 05:21 PM
McSharry Heather AnnDirectorAug 14Sale138.161,344185,68516,778Aug 15 05:52 PM
O'Keefe Kenneth WDirectorAug 14Sale138.161,241171,45524,723Aug 15 07:49 PM
ENRIGHT PATRICK GDirectorAug 14Sale138.161,241171,45520,946Aug 15 05:45 PM
Sohn Catherine A.DirectorAug 14Sale138.161,241171,45514,868Aug 15 06:02 PM
Winningham Rick EDirectorAug 14Sale138.161,241171,45510,444Aug 15 06:08 PM
Gray PeterDirectorAug 14Sale138.161,241171,45516,068Aug 15 05:47 PM
Cook Jennifer E.DirectorAug 14Sale138.161,241171,4547,305Aug 15 05:44 PM
RIEDEL NORBERT GDirectorAug 14Sale138.161,241171,45413,705Aug 15 05:58 PM
ORiordan AnneDirectorAug 14Sale138.161,241171,45412,551Aug 15 07:51 PM
Smith Mark DouglasDirectorAug 14Sale138.161,241171,4547,305Aug 15 06:00 PM
Carr PatriciaSVP, Chief Accounting OfficerAug 14Sale138.1615821,8296,128Aug 15 05:43 PM
Mulligan SeamusDirectorJun 08Option Exercise81.764,500367,9201,169,300Jun 12 04:47 PM
Carr PatriciaSVP, Chief Accounting OfficerJun 07Sale127.9212616,1176,286Jun 09 04:55 PM
Patil Neena MEVP & Chief Legal OfficerJun 01Sale127.981,600204,76332,826Jun 05 08:24 PM
GALA RENEE DEVP & Chief Financial OfficerMay 18Sale131.756,000790,47435,978May 19 08:45 PM
Carr PatriciaSVP, Chief Accounting OfficerMar 15Sale133.221,023136,2846,286Mar 17 06:10 PM
Sablich KimEVP, GM of U.S., Commercial MaMar 08Sale139.743,013421,04330,560Mar 10 06:10 PM
O'Keefe Kenneth WDirectorMar 07Option Exercise81.764,500367,92025,579Mar 09 06:34 PM
O'Keefe Kenneth WDirectorMar 07Sale138.392,690372,26722,889Mar 09 06:34 PM
Larkin FinbarSVP, Technical OperationsMar 07Sale140.762,075292,08121,779Mar 07 09:33 PM
Larkin FinbarSVP, Technical OperationsMar 06Option Exercise58.721,706100,17625,560Mar 07 09:33 PM
Larkin FinbarSVP, Technical OperationsMar 06Sale143.921,706245,52623,854Mar 07 09:33 PM
Carr PatriciaSVP, Chief Accounting OfficerMar 05Sale140.761,148161,5947,309Mar 07 09:18 PM
Mulligan SeamusDirectorMar 04Option Exercise59.134,500266,0851,164,800Mar 07 08:30 PM
Pearce SamanthaSVP, Head of Europe & InternatFeb 02Option Exercise109.4553158,11811,840Feb 06 04:26 PM
Pearce SamanthaSVP, Head of Europe & InternatFeb 02Sale157.2653183,50511,309Feb 06 04:26 PM
COZADD BRUCE CChairman & CEOFeb 01Sale155.791,000155,790367,078Feb 03 06:45 PM
Pearce SamanthaSVP, Head of Europe & InternatJan 03Option Exercise109.4553158,11811,840Jan 05 06:43 PM
COZADD BRUCE CChairman & CEOJan 03Sale159.863,000479,590368,078Jan 05 06:41 PM
Pearce SamanthaSVP, Head of Europe & InternatJan 03Sale159.5953184,74211,309Jan 05 06:43 PM
GALA RENEE DEVP & Chief Financial OfficerDec 21Sale160.002,635421,60032,558Dec 22 04:53 PM
Pearce SamanthaSVP, Head of Europe & InternatDec 13Option Exercise109.4553158,11811,840Dec 15 06:29 PM
Pearce SamanthaSVP, Head of Europe & InternatDec 13Sale155.4553182,54411,309Dec 15 06:29 PM
Iannone RobertEVP, Global Head of R&DDec 09Sale151.541,844279,44036,316Dec 13 05:16 PM
Carr PatriciaSVP, Chief Accounting OfficerDec 05Sale152.06639,5805,934Dec 07 06:38 PM
Smith Mark DouglasDirectorDec 02Sale154.6842064,9665,471Dec 06 06:57 PM
Cook Jennifer E.DirectorDec 02Sale154.6842064,9665,471Dec 06 07:01 PM
COZADD BRUCE CChairman & CEODec 01Sale157.001,000157,000371,078Dec 05 05:03 PM